Topics covered: Theranostics: Merger of Diagnostics and Drugs, Regulatory Reform & Reimbursements, Laboratory Developed Tests
Companies covered: Cerner Corporation (NASDAQ:CERN), Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), Waters Corporation (NYSE:WAT), Thermo Fisher Scientific Inc (NYSE:TMO), Pharmaceutical Product Develop, MedcoHealth Solutions Inc., McKesson Corporation (NYSE:MCK), Life Technologies Corporation, Intel Corporation (NASDAQ:INTC), Illumina, Inc. (NASDAQ:ILMN), ICON plc (NASDAQ:ICLR), Express Scripts Holding Company (NASDAQ:ESRX), Covance Inc. (NYSE:CVD), Charles River Laboratories International, Inc. (NYSE:CRL), Cardinal Health, Inc. (NYSE:CAH), AmerisourceBergen Corporation (Holding Co) (NYSE:ABC), Agilent Technologies, Inc. (NYSE:A), CEPHEID (NASDAQ:CPHD), Bruker Corporation (NASDAQ:BRKR), Bio-Techne Corp (NASDAQ:TECH), Meridian Bioscience Inc. (NASDAQ:VIVO), SeraCare Life Sciences Inc., PAREXEL International Corporation (NASDAQ:PRXL), Kendle International Inc., EXACT Sciences Corporation (NASDAQ:EXAS), BioSpecifics Technologies Corp (NASDAQ:BSTC), Targacept, Inc. (NASDAQ:TRGT), Savient Pharmaceuticals Inc., Ardea Biosciences, Inc., Pfizer, Inc. (NYSE:PFE), PDL BioPharma, Inc. (NASDAQ:PDLI), Myriad Genetics, Inc. (NASDAQ:MYGN), Medivation, Inc. (NASDAQ:MDVN), King Pharmaceuticals Inc., GlaxoSmithKline PLC (NYSE:GSK), Dyax Corp. (NASDAQ:DYAX), Discovery Laboratories, Inc. (NASDAQ:DSCO), Dendreon Corp., Corcept Therapeutics Incorporated (NASDAQ:CORT), AstraZeneca PLC (NASDAQ:AZN), Auxilium Pharmaceuticals Inc., Celgene Corporation (NASDAQ:CELG), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), Gilead Sciences, Inc. (NASDAQ:GILD), Genzyme Corp., Amylin Pharmaceuticals Inc., Thoratec Corporation (NASDAQ:THOR), Qiagen N.V. (NASDAQ:QGEN), Medtronic, Inc. (NYSE:MDT), Luminex Corporation (NASDAQ:LMNX), Hologic, Inc. (NASDAQ:HOLX), GoPro, Inc. (NASDAQ:GPRO), Edwards Lifesciences Corporation (NYSE:EW), Beckman Coulter Inc., Array BioPharma Inc. (NASDAQ:ARRY), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Sanofi (NYSE:SNY), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Onyx Pharmaceuticals Inc., OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Novartis AG (NYSE:NVS), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), MannKind Corporation (NASDAQ:MNKD), Eli Lilly and Company (NYSE:LLY), Human Genome Sciences Inc., GTx, Inc. (NASDAQ:GTXI), Exelixis, Inc. (NASDAQ:EXEL), NanoViricides, Inc. (NYSEAMERICAN:NNVC), Cleveland BioLabs, Inc. (NASDAQ:CBLI), BioTime, Inc. (AMEX:BTX), Loral Space and Communications, Inc. (NASDAQ:LORL), HealthSpring Inc., Ace Limited (NYSE:ACE), Genesis Energy, L.P. (NYSE:GEL), Chesapeake Energy Corporation (NYSE:CHK)
